Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)

NCT06162221 is registered in ClinicalTrials.gov with Revolution Medicines, Inc. as lead sponsor.

NCT NCT06162221
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06162221 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
Revolution Medicines, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 18, 2024
Completion date
December 31, 2028
Enrollment
616 (estimated)
Sites
93

Conditions

As the registry lists them; a condition with its own page is linked.

kras g12c-mutated solid tumors, lung cancer, kras, nras, hras-mutated nsclc, lung cancer stage iv, advanced solid tumor, cancer, non-small cell lung cancer, nsclc, ras g12d-mutated nsclc